Apollomics Inc.
Moat Score — Apollomics Inc.
Total Moat Score
7 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Apollomics holds patents on vebreltinib and its broader oncology pipeline, but as a later entrant behind two already-approved MET inhibitors (capmatinib and tepotinib), its intellectual property provides less differentiation than a true first-in-class asset would. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a small clinical-stage biotech, Apollomics has no manufacturing or commercial scale cost advantage versus large oncology incumbents like Novartis and Merck. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | If approved, oncology specialty pricing is generally supportable, but Apollomics would price relative to two already-established competing MET inhibitors rather than setting a novel price point as a first-in-class entrant. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | A targeted oncology therapy exhibits no network effect between patients or prescribers. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Oncologists can select among approved MET inhibitors based on patient-specific factors and clinical trial data with relatively low switching friction, since treatment selection typically occurs at diagnosis or progression rather than requiring migration from an existing therapy. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The MET exon 14 skipping NSCLC population is a genetically narrow niche, but two competitors are already established there, so incremental efficient-scale protection for a third entrant like Apollomics is limited. |